Parvis Farahmand
Overview
Explore the profile of Parvis Farahmand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spiegel R, Claassen J, Teufel J, Bardins S, Schneider E, Lehrer Rettinger N, et al.
Ann N Y Acad Sci
. 2016 Jul;
1375(1):66-73.
PMID: 27447539
Resting in an upright position during daytime decreases downbeat nystagmus (DBN). When measured in brightness only, that is, without intermitting exposure to darkness, it does not make a significant difference...
2.
Gluer C, Marin F, Ringe J, Hawkins F, Moricke R, Papaioannu N, et al.
J Bone Miner Res
. 2013 Jan;
28(6):1355-68.
PMID: 23322362
Data on treatment of glucocorticoid-induced osteoporosis (GIO) in men are scarce. We performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for ≥3 months, and had an...
3.
Spiegel R, Kalla R, Classen J, Bardins S, da Silva F, Farahmand P, et al.
J Neuroophthalmol
. 2012 Apr;
32(2):190.
PMID: 22487785
No abstract available.
4.
Spiegel R, Farahmand P, da Silva F, Claassen J, Kalla R
Traffic Inj Prev
. 2012 Jan;
13(1):49-54.
PMID: 22239143
Objective: The objective of this article is to determine how to prevent road injuries in schoolchildren by reducing the prevalence of speeding. Methods: On a busy road in the neighborhood...
5.
Ringe J, Dorst A, Farahmand P
Arzneimittelforschung
. 2010 Jun;
60(5):267-72.
PMID: 20533764
In an open-label, prospective, controlled, 12-month study the effects of strontium ranelate (SR, CAS 135459-87-9) or alendronate (CAS 129318-43-0) on bone mineral density (BMD) were compared in 152 men with...
6.
Ringe J, Farahmand P, Faber H, Dorst A
Rheumatol Int
. 2008 Sep;
29(3):311-5.
PMID: 18762944
The aim of this study was to assess the effect of treatment with risedronate 5 mg daily relative to control in men with primary or secondary osteoporosis over 2 years....
7.
Ringe J, Farahmand P
Clin Rheumatol
. 2006 Nov;
26(4):474-84.
PMID: 17122953
Corticosteroids are widely used as anti-inflammatory and immunosuppressive agents to treat a variety of chronic conditions. Long-term (>1 year) corticosteroid use can lead to bone loss, and therefore, osteopenia or...
8.
Ringe J, Faber H, Farahmand P
J Bone Miner Metab
. 2005 Dec;
24(1):87-93.
PMID: 16369904
Sternocostoclavicular hyperostosis (SCCH) is an infrequent but painful, localized disturbance of bone metabolism of unknown etiology. The diagnosis of SCCH is generally one of exclusion, and it is therefore frequently...